DARS2 and tuberculosis: A rhodanine compound was previously identified to target the aspartyl-tRNA synthetase of TB by WGS approaches19, which was then biochemically validated in a tRNA-independent assay20, encouraging further screening campaigns to find more potent and chemically tractable hits against this target.